

Robert A Kyle

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9461738/publications.pdf>

Version: 2024-02-01

482
papers

38,733
citations

7568

77
h-index

3034

188
g-index

488
all docs

488
docs citations

488
times ranked

18083
citing authors

#	ARTICLE	IF	CITATIONS
1	Mortality trends in multiple myeloma after the introduction of novel therapies in the United States. <i>Leukemia</i> , 2022, 36, 801-808.	7.2	43
2	Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myeloma. <i>Leukemia</i> , 2022, 36, 873-876.	7.2	12
3	Family history of plasma cell disorders is associated with improved survival in MGUS, multiple myeloma, and systemic AL amyloidosis. <i>Leukemia</i> , 2022, 36, 1058-1065.	7.2	3
4	Characteristics and risk factors for thrombosis in <scp>POEMS</scp> syndrome: A retrospective evaluation of 230 patients. <i>American Journal of Hematology</i> , 2022, 97, 209-215.	4.1	5
5	Suzanne Gros NoÃ«l: Plastic Surgery Pioneer and Advocate for Womenâ€™s Rights. <i>Mayo Clinic Proceedings</i> , 2022, 97, 196-197.	3.0	0
6	Impact of achieving a complete response to initial therapy of multiple myeloma and predictors of subsequent outcome. <i>American Journal of Hematology</i> , 2022, , .	4.1	5
7	A simple additive staging system for newly diagnosed multiple myeloma. <i>Blood Cancer Journal</i> , 2022, 12, 21.	6.2	30
8	Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab. <i>Leukemia</i> , 2022, 36, 1426-1428.	7.2	7
9	Multicentric Castleman disease: A single center experience of treatment with a focus on autologous stem cell transplantation. <i>American Journal of Hematology</i> , 2022, , .	4.1	2
10	Detection of Plasma Cell Disorders by Mass Spectrometry: A Comprehensive Review of 19,523 Cases. <i>Mayo Clinic Proceedings</i> , 2022, 97, 294-307.	3.0	16
11	Monoclonal proteinuria predicts progression risk in asymptomatic multiple myeloma with a free light chain ratio â‰¥100. <i>Leukemia</i> , 2022, 36, 1429-1431.	7.2	8
12	Samuel Gridley Howe: Abolitionist, Physician, and Pioneer in Education of Children With Vision Loss and Mental Disability. <i>Mayo Clinic Proceedings</i> , 2022, 97, 633-635.	3.0	0
13	Success of the autologous stem cell boost after autologous graft failure in multiple myeloma and AL amyloidosis. <i>Bone Marrow Transplantation</i> , 2022, , .	2.4	0
14	Body mass index associated with monoclonal gammopathy of undetermined significance (MGUS) progression in Olmsted County, Minnesota. <i>Blood Cancer Journal</i> , 2022, 12, 67.	6.2	13
15	Commercial Advertising on Postage Stamps: The Curious Case of Dr Francis Macbean Stewartâ€™s Miracle Cure. <i>Mayo Clinic Proceedings</i> , 2022, 97, 1029-1032.	3.0	0
16	Bendamustine rituximab (BR) versus ibrutinib (Ibr) as primary therapy for WaldenstrÃ¶m macroglobulinemia (WM): An international collaborative study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7566-7566.	1.6	9
17	Impact of high-dose melphalan followed by autologous stem cell transplant in producing MRD negative complete response in newly diagnosed multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2022, 40, e20001-e20001.	1.6	0
18	Insurance-based disparities in WaldenstrÃ¶m Macroglobulinemia: An NCDB analysis.. <i>Journal of Clinical Oncology</i> , 2022, 40, e19562-e19562.	1.6	0

#	ARTICLE	IF	CITATIONS
19	Characterization and prognostic implication of delayed complete response in AL amyloidosis. European Journal of Haematology, 2021, 106, 354-361.	2.2	4
20	Implications of detecting serum monoclonal protein by MASSaFix following stem cell transplantation in multiple myeloma. British Journal of Haematology, 2021, 193, 380-385.	2.5	21
21	Outcomes with different administration schedules of bortezomib in bortezomib, lenalidomide and dexamethasone (<scp>VRd</scp>) as first-line therapy in multiple myeloma. American Journal of Hematology, 2021, 96, 330-337.	4.1	13
22	Treatment facility volume and patient outcomes in Waldenström macroglobulinemia. Leukemia and Lymphoma, 2021, 62, 308-315.	1.3	3
23	Retroperitoneal involvement with light chain amyloidosis- case series and literature review. Leukemia and Lymphoma, 2021, 62, 316-322.	1.3	2
24	Kaare Nygaard: Surgeon, Scientist, Sculptor. Mayo Clinic Proceedings, 2021, 96, e7-e8.	3.0	0
25	Disease monitoring with quantitative serum IgA levels provides a more reliable response assessment in multiple myeloma patients. Leukemia, 2021, 35, 1428-1437.	7.2	8
26	Prognosis of young patients with monoclonal gammopathy of undetermined significance (MGUS). Blood Cancer Journal, 2021, 11, 26.	6.2	10
27	Coagulation Abnormalities in Light Chain Amyloidosis. Mayo Clinic Proceedings, 2021, 96, 377-387.	3.0	12
28	Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. British Journal of Haematology, 2021, 194, 496-507.	2.5	67
29	James Till and Ernest McCulloch: Hematopoietic Stem Cell Discoverers. Mayo Clinic Proceedings, 2021, 96, 830-831.	3.0	5
30	Clinical Characteristics and Outcomes of Patients With Primary Plasma Cell Leukemia in the Era of Novel Agent Therapy. Mayo Clinic Proceedings, 2021, 96, 677-687.	3.0	16
31	MASS-FIX for the detection of monoclonal proteins and light chain N-glycosylation in routine clinical practice: a cross-sectional study of 6315 patients. Blood Cancer Journal, 2021, 11, 50.	6.2	25
32	Prognostic impact of depth of response in Waldenström macroglobulinemia patients treated with fixed duration chemoimmunotherapy.. Journal of Clinical Oncology, 2021, 39, 8049-8049.	1.6	1
33	Impact of stratifying levels of serum lactate dehydrogenase (LDH) at diagnosis on the overall survival (OS) in newly diagnosed multiple myeloma (NDMM).. Journal of Clinical Oncology, 2021, 39, e20016-e20016.	1.6	0
34	Emile Letournel: Pioneer of Acetabular Surgery. Mayo Clinic Proceedings, 2021, 96, 1379-1380.	3.0	1
35	Progression from Monoclonal gammopathy of undetermined significance of the immunoglobulin M class (IgM-MGUS) to Waldenström Macroglobulinemia is associated with an alteration in lipid metabolism. Redox Biology, 2021, 41, 101927.	9.0	4
36	Assessment of fixed-duration therapies for treatment-naïve <scp>Waldenström</scp> macroglobulinemia. American Journal of Hematology, 2021, 96, 945-953.	4.1	12

#	ARTICLE	IF	CITATIONS
37	Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update. Mayo Clinic Proceedings, 2021, 96, 1546-1577.	3.0	32
38	The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma: A Cross-analysis of a Population-based Registry and a Tertiary Care Center. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 451-460.e2.	0.4	9
39	Second Stem Cell Transplantation for Relapsed Refractory Light Chain (AL) Amyloidosis. Transplantation and Cellular Therapy, 2021, 27, 589.e1-589.e6.	1.2	3
40	Treatment and outcome of newly diagnosed multiple myeloma patients > 75 years old: a retrospective analysis. Leukemia and Lymphoma, 2021, 62, 3011-3018.	1.3	2
41	Venetoclax for the treatment of multiple myeloma: Outcomes outside of clinical trials. American Journal of Hematology, 2021, 96, 1131-1136.	4.1	21
42	Albin Lambotte: Pioneer of Osteosynthesis (Bone Fixation). Mayo Clinic Proceedings, 2021, 96, 2012-2013.	3.0	2
43	MALDI-TOF mass spectrometry can distinguish immunofixation bands of the same isotype as monoclonal or biclonal proteins. Clinical Biochemistry, 2021, 97, 67-73.	1.9	4
44	Disease outcomes and biomarkers of progression in smouldering Waldenström macroglobulinaemia. British Journal of Haematology, 2021, 195, 210-216.	2.5	12
45	Dr John H. Watson: Sherlock Holmes™ Companion and Biographer. Mayo Clinic Proceedings, 2021, 96, 2500-2502.	3.0	0
46	The Effect of Duration of Lenalidomide Maintenance and Outcomes of Different Salvage Regimens in Patients with Multiple Myeloma (MM). Blood Cancer Journal, 2021, 11, 158.	6.2	9
47	Comparison of the current renal staging, progression and response criteria to predict renal survival in <sc>AL</sc> amyloidosis using a <sc>Mayo</sc> cohort. American Journal of Hematology, 2021, 96, 446-454.	4.1	8
48	Prognostic significance of acquired 1q22 gain in multiple myeloma. American Journal of Hematology, 2021, , .	4.1	6
49	M. Vera Peters: Pioneering Radiation Oncologist. Mayo Clinic Proceedings, 2021, 96, 2927-2928.	3.0	0
50	"Real-Life" Data of the Efficacy and Safety of Belantamab Mafodotin in Relapsed Multiple Myeloma- the Mayo Clinic Experience. Blood, 2021, 138, 1639-1639.	1.4	3
51	Tracking Daratumumab Clearance Using Mass Spectrometric Approaches: Implications on M Protein Monitoring and Reusing Daratumumab. Blood, 2021, 138, 2707-2707.	1.4	0
52	An Analysis of Virus Amplification and Antitumor Responses in T-Cell Lymphoma Patients Treated with Voyager-V1 (VSV-IFN γ -NIS). Blood, 2021, 138, 1333-1333.	1.4	0
53	Prognostic Role of IL-6 in POEMS Syndrome. Blood, 2021, 138, 2700-2700.	1.4	0
54	Monoclonal Proteinuria Predicts Progression Risk in Asymptomatic Multiple Myeloma with a Free Light Chain Ratio \geq 100. Blood, 2021, 138, 1617-1617.	1.4	0

#	ARTICLE	IF	CITATIONS
55	Second Line Treatment Strategies in Multiple Myeloma: A Referral-Center Experience. Blood, 2021, 138, 819-819.	1.4	1
56	Amyloidosis Composite Response Score Incorporating the Depth of Organ Response. Blood, 2021, 138, 3805-3805.	1.4	0
57	Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis. Blood Cancer Journal, 2021, 11, 186.	6.2	8
58	Outcomes Following Biochemical or Clinical Progression in Patients with Multiple Myeloma. Blood, 2021, 138, 3760-3760.	1.4	1
59	Impact of Achieving an Early Complete Response in Multiple Myeloma and Predictors of Subsequent Outcome. Blood, 2021, 138, 3773-3773.	1.4	0
60	Prognostic Factors for Early (<2 years) and Late (>5 years) Relapse in Multiple Myeloma- Pivotal Role of Cytogenetic Changes. Blood, 2021, 138, 3761-3761.	1.4	0
61	Outcomes of Triple Class (Proteasome Inhibitor, IMiDs and Monoclonal Antibody) Refractory Patients with Multiple Myeloma. Blood, 2021, 138, 1632-1632.	1.4	0
62	The Prognostic Utility of Serial MASS-FIX in Multiple Myeloma. Blood, 2021, 138, 1619-1619.	1.4	0
63	Assessing the Prognostic Utility of the Mayo 2018 and IMWG 2020 Smoldering Multiple Myeloma Risk Stratification Scores When Applied Post Diagnosis. Blood, 2021, 138, 543-543.	1.4	0
64	Factors Associated with Renal Impairment at Diagnosis in Multiple Myeloma with Survival Trends over Last Two Decades. Blood, 2021, 138, 1630-1630.	1.4	0
65	Mortality Trends in Multiple Myeloma after the Introduction of Novel Therapies in the United States. Blood, 2021, 138, 119-119.	1.4	0
66	The Impact of the Central Carbon Energy Metabolism Transcriptome in the Pathogenesis and Outcomes of Multiple Myeloma. Blood, 2021, 138, 2650-2650.	1.4	0
67	Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage. Blood Cancer Journal, 2021, 11, 192.	6.2	62
68	Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 13-16.	3.0	25
69	MYC dysregulation in the progression of multiple myeloma. Leukemia, 2020, 34, 322-326.	7.2	108
70	Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomes. British Journal of Haematology, 2020, 188, 394-403.	2.5	41
71	Hematopoietic score predicts outcomes in newly diagnosed multiple myeloma patients. American Journal of Hematology, 2020, 95, 4-9.	4.1	14
72	Cytogenetic Features and Clinical Outcomes of Patients With Non-secretory Multiple Myeloma in the Era of Novel Agent Induction Therapy. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 53-56.	0.4	8

#	ARTICLE	IF	CITATIONS
73	Alexandre Yersin: Discoverer of the Plague Bacillus. Mayo Clinic Proceedings, 2020, 95, e7-e8.	3.0	6
74	Enhancing the Râ€SS classification of newly diagnosed multiple myeloma by quantifying circulating clonal plasma cells. American Journal of Hematology, 2020, 95, 310-315.	4.1	37
75	Implications and outcomes of MRDâ€negative multiple myeloma patients with immunofixation positivity. American Journal of Hematology, 2020, 95, E60-E62.	4.1	4
76	Impact of MYD88^{L265P} mutation status on histological transformation of WaldenstrÃ¶m Macroglobulinemia. American Journal of Hematology, 2020, 95, 274-281.	4.1	33
77	IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features. Leukemia, 2020, 34, 1373-1382.	7.2	40
78	Revisiting complete response in light chain amyloidosis. Leukemia, 2020, 34, 1472-1475.	7.2	15
79	Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis. Leukemia, 2020, 34, 1135-1143.	7.2	29
80	Colon perforation in multiple myeloma patients â€“ A complication of highâ€dose steroid treatment. Cancer Medicine, 2020, 9, 8895-8901.	2.8	3
81	Implications of MYC Rearrangements in Newly Diagnosed Multiple Myeloma. Clinical Cancer Research, 2020, 26, 6581-6588.	7.0	32
82	Utility of repeating bone marrow biopsy for confirmation of complete response in multiple myeloma. Blood Cancer Journal, 2020, 10, 95.	6.2	3
83	Refining amyloid complete hematological response: Quantitative serum free light chains superior to ratio. American Journal of Hematology, 2020, 95, 1280-1287.	4.1	17
84	Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response. Blood Cancer Journal, 2020, 10, 82.	6.2	59
85	Fernando Figueira: Brazilian Public Health Champion. Mayo Clinic Proceedings, 2020, 95, e97-e98.	3.0	0
86	Correlation between urine ACR and 24-h proteinuria in a real-world cohort of systemic AL amyloidosis patients. Blood Cancer Journal, 2020, 10, 124.	6.2	12
87	Roald Dahl: Childrenâ€™s Book Author, Medical Device Inventor, Myelodysplastic Syndrome Patient, and Philanthropist. Mayo Clinic Proceedings, 2020, 95, e119-e120.	3.0	0
88	The role of bone marrow biopsy in patients with plasma cell disorders: should all patients with a monoclonal protein be biopsied?. Blood Cancer Journal, 2020, 10, 52.	6.2	8
89	Monoclonal Gammopathy of Undetermined Significance: Indications for Prediagnostic Testing, Subsequent Diagnoses, and Follow-up Practice at Mayo Clinic. Mayo Clinic Proceedings, 2020, 95, 944-954.	3.0	7
90	Razi: Critical Thinker, and Pioneer of Infectious Disease and Ophthalmology. Mayo Clinic Proceedings, 2020, 95, e53-e54.	3.0	0

#	ARTICLE	IF	CITATIONS
91	Outcomes with early vs. deferred stem cell transplantation in light chain amyloidosis. Bone Marrow Transplantation, 2020, 55, 1297-1304.	2.4	5
92	Recognizing “diagnostic futility”—stopping earlier to protect patients. American Journal of Hematology, 2020, 95, 580-582.	4.1	0
93	Utilizing multiparametric flow cytometry in the diagnosis of patients with primary plasma cell leukemia. American Journal of Hematology, 2020, 95, 637-642.	4.1	12
94	Blood mass spectrometry detects residual disease better than standard techniques in light-chain amyloidosis. Blood Cancer Journal, 2020, 10, 20.	6.2	26
95	Long-term outcomes of IMiD-based trials in patients with immunoglobulin light-chain amyloidosis: a pooled analysis. Blood Cancer Journal, 2020, 10, 4.	6.2	18
96	Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosis. American Journal of Hematology, 2020, 95, 497-502.	4.1	35
97	Increased Bone Marrow Plasma-Cell Percentage Predicts Outcomes in Newly Diagnosed Multiple Myeloma Patients. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 596-601.	0.4	15
98	MASS-FIX for the Diagnosis of Plasma Cell Disorders: A Single Institution Experience of 4118 Patients. Blood, 2020, 136, 48-49.	1.4	2
99	Continued Improvement in Survival of Patients with Newly Diagnosed Multiple Myeloma (MM). Blood, 2020, 136, 30-31.	1.4	4
100	Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon Beta, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL). Blood, 2020, 136, 7-8.	1.4	1
101	Sequential Comparison of Conventional Serum Immunofixation (IFE) to Mass Spectrometry-Based Assessment (MASS FIX) in Patients with Multiple Myeloma (MM). Blood, 2020, 136, 12-13.	1.4	3
102	Comparison of Conventional Xrays with CT Based Approaches for Detection of Lytic Lesions in Multiple Myeloma. Blood, 2020, 136, 27-28.	1.4	0
103	The Prognostic Significance of Acquired 1q22 Gain in Multiple Myeloma. Blood, 2020, 136, 9-10.	1.4	0
104	Comparison of MGUS Prevalence By Race and Family History Risk Groups Using a High Sensitivity Screening Method (MASS-FIX). Blood, 2020, 136, 40-41.	1.4	1
105	A Cross Sectional Evaluation of Light Chain N-Glycosylation By MASS-FIX in Plasma Cell Disorders. Blood, 2020, 136, 44-45.	1.4	0
106	Prognostic Impact of PET Findings Post-Transplant in Multiple Myeloma. Blood, 2020, 136, 15-16.	1.4	0
107	Treatments and Outcomes of Newly Diagnosed Multiple Myeloma Patients > 75 Years Old: A Retrospective Analysis. Blood, 2020, 136, 14-15.	1.4	0
108	Prognostic Restaging after Treatment Initiation in Patients with AL Amyloidosis. Blood, 2020, 136, 6-7.	1.4	0

#	ARTICLE	IF	CITATIONS
109	Body Mass Index and Clinical Factors Associated with Monoclonal Gammopathy of Undetermined Significance (MGUS) Progression in Olmsted County, Minnesota. <i>Blood</i> , 2020, 136, 15-16.	1.4	0
110	A 3-Question Symptom Assessment Score Can Predict Outcomes in Newly Diagnosed Multiple Myeloma (MM). <i>Blood</i> , 2020, 136, 21-22.	1.4	0
111	Unmet Needs in AL Amyloidosis: Outcomes in the Modern Era Among the Highest Risk, Newly Diagnosed AL Amyloidosis Patients. <i>Blood</i> , 2020, 136, 31-32.	1.4	1
112	Retroperitoneal Involvement of Light Chain Amyloidosis-Case Series and Literature Review. <i>Blood</i> , 2020, 136, 37-38.	1.4	0
113	Prevalence of Familial Plasma Cell Disorders in Patients with Multiple Myeloma. <i>Blood</i> , 2020, 136, 1-2.	1.4	0
114	Waldenström Macroglobulinemia in the Very Elderly (>75 years):Clinical Characteristics and Outcomes. <i>Blood</i> , 2020, 136, 44-45.	1.4	8
115	Peripheral blood biomarkers of early immune reconstitution in newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , 2019, 94, 306-311.	4.1	18
116	Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement. <i>Bone Marrow Transplantation</i> , 2019, 54, 353-367.	2.4	81
117	Ten-year survivors in AL amyloidosis: characteristics and treatment pattern. <i>British Journal of Haematology</i> , 2019, 187, 588-594.	2.5	40
118	Andreas Vesalius and De Fabrica. <i>Mayo Clinic Proceedings</i> , 2019, 94, e67-e68.	3.0	5
119	Depth of organ response in AL amyloidosis is associated with improved survival: new proposed organ response criteria. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2019, 26, 101-102.	3.0	9
120	Characteristics of long-term survivors with multiple myeloma: A National Cancer Data Base analysis. <i>Cancer</i> , 2019, 125, 3574-3581.	4.1	7
121	Albert Schweitzer: Humanitarian With a "Reverence for Life". <i>Mayo Clinic Proceedings</i> , 2019, 94, e91-e92.	3.0	2
122	Comparative analysis of staging systems in AL amyloidosis. <i>Leukemia</i> , 2019, 33, 811-814.	7.2	22
123	John Shaw Billings: Civil War Surgeon, Medical Librarian, Founder of Index Medicus, and First Director of the New York Public Library. <i>Mayo Clinic Proceedings</i> , 2019, 94, e45-e46.	3.0	11
124	Polyclonal serum free light chain elevation is associated with increased risk of monoclonal gammopathies. <i>Blood Cancer Journal</i> , 2019, 9, 49.	6.2	11
125	Development of thrombocytopenia during first-line treatment and survival outcomes in newly diagnosed multiple myeloma. <i>Leukemia and Lymphoma</i> , 2019, 60, 2960-2967.	1.3	4
126	Clinical features, laboratory characteristics and outcomes of patients with renal <i>versus</i> cardiac light chain amyloidosis. <i>British Journal of Haematology</i> , 2019, 185, 701-707.	2.5	17

#	ARTICLE	IF	CITATIONS
127	Natural history of multiple myeloma with de novo del(17p). Blood Cancer Journal, 2019, 9, 32.	6.2	38
128	Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy. American Journal of Hematology, 2019, 94, 751-756.	4.1	15
129	Incidence of AL Amyloidosis in Olmsted County, Minnesota, 1990 through 2015. Mayo Clinic Proceedings, 2019, 94, 465-471.	3.0	87
130	Substratification of patients with newly diagnosed standard-risk multiple myeloma. British Journal of Haematology, 2019, 185, 254-260.	2.5	12
131	Prognostic restaging at the time of second-line therapy in patients with AL amyloidosis. Leukemia, 2019, 33, 1268-1272.	7.2	7
132	The role of cement augmentation with percutaneous vertebroplasty and balloon kyphoplasty for the treatment of vertebral compression fractures in multiple myeloma: a consensus statement from the International Myeloma Working Group (IMWG). Blood Cancer Journal, 2019, 9, 27.	6.2	53
133	Monoclonal gammopathy plus positive amyloid biopsy does not always equal AL amyloidosis. American Journal of Hematology, 2019, 94, E141-E143.	4.1	17
134	Impact of prior diagnosis of monoclonal gammopathy on outcomes in newly diagnosed multiple myeloma. Leukemia, 2019, 33, 1273-1277.	7.2	12
135	A Modern Primer on Light Chain Amyloidosis in 592 Patients With Mass Spectrometry-Verified Typing. Mayo Clinic Proceedings, 2019, 94, 472-483.	3.0	59
136	Impact of acquired del(17p) in multiple myeloma. Blood Advances, 2019, 3, 1930-1938.	5.2	41
137	Luke Fildes and The Doctor. Mayo Clinic Proceedings, 2019, 94, e131-e132.	3.0	1
138	Detection and prevalence of monoclonal gammopathy of undetermined significance: a study utilizing mass spectrometry-based monoclonal immunoglobulin rapid accurate mass measurement. Blood Cancer Journal, 2019, 9, 102.	6.2	57
139	Risk of MGUS in relatives of multiple myeloma cases by clinical and tumor characteristics. Leukemia, 2019, 33, 499-507.	7.2	9
140	Rapid assessment of hyperdiploidy in plasma cell disorders using a novel multi-parametric flow cytometry method. American Journal of Hematology, 2019, 94, 424-430.	4.1	11
141	Primary systemic amyloidosis in patients with Waldenström macroglobulinemia. Leukemia, 2019, 33, 790-794.	7.2	28
142	Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse. Leukemia, 2019, 33, 730-738.	7.2	20
143	The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group. Nature Reviews Nephrology, 2019, 15, 45-59.	9.6	330
144	Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio. Leukemia, 2019, 33, 527-531.	7.2	36

#	ARTICLE	IF	CITATIONS
145	Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis. <i>Leukemia</i> , 2019, 33, 531-536.	7.2	72
146	Prevalence and survival of smouldering Waldenström macroglobulinaemia in the United States. <i>British Journal of Haematology</i> , 2019, 184, 1014-1017.	2.5	20
147	Mortality of Patients with Multiple Myeloma after the Introduction of Novel Therapies in the United States. <i>Blood</i> , 2019, 134, 72-72.	1.4	2
148	Utilizing Multiparametric Flow Cytometry to Identify Patients with Primary Plasma Cell Leukemia at Diagnosis. <i>Blood</i> , 2019, 134, 4334-4334.	1.4	1
149	Prognostic Implications of Serum Monoclonal Protein Positivity By Mass-Fix in Bone Marrow Minimal Residual Disease Negative (MRD-) Patients with Multiple Myeloma. <i>Blood</i> , 2019, 134, 4386-4386.	1.4	2
150	Phase 2 Trial of LDE225 and Lenalidomide Maintenance Post Autologous Stem Cell Transplant for Multiple Myeloma. <i>Blood</i> , 2019, 134, 1905-1905.	1.4	2
151	Hypovitaminosis D Is Prevalent in Patients with Renal AL Amyloidosis and Associated with Non-t(11;14). <i>Blood</i> , 2019, 134, 5523-5523.	1.4	0
152	Waldenström Macroglobulinemia with Excess Plasma Cells: Is It a Distinct Entity?. <i>Blood</i> , 2019, 134, 1532-1532.	1.4	0
153	Metaphase Cytogenetics for Risk Stratification in Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2019, 134, 4396-4396.	1.4	0
154	Impact of sFLC Ratio on Outcome in Patients with MM: Validating the Utility of sFLC in Response Definition. <i>Blood</i> , 2019, 134, 3080-3080.	1.4	0
155	Long Non-Coding RNA Expression in Waldenstrom Macroglobulinemia and IgM Monoclonal Gammopathy of Undetermined Significance. <i>Blood</i> , 2019, 134, 2774-2774.	1.4	0
156	Phase 2 Trial of Ixazomib, Cyclophosphamide and Dexamethasone in Relapsed Multiple Myeloma. <i>Blood</i> , 2019, 134, 1904-1904.	1.4	0
157	Increased Mean Corpuscular Volume Is an Independent Predictor for Worse Overall Survival in Patients with Newly Diagnosed Light Chain Amyloidosis. <i>Blood</i> , 2019, 134, 5532-5532.	1.4	0
158	A Novel Approach to Risk Stratification in Multiple Myeloma Using ISS Stage and FISH. <i>Blood</i> , 2019, 134, 1800-1800.	1.4	1
159	The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2019, 134, 2197-2197.	1.4	0
160	Clinical Outcomes and Cytogenetic Features of Primary Plasma Cell Leukemia (pPCL) in the Era of Novel Agent Induction Therapy. <i>Blood</i> , 2019, 134, 5490-5490.	1.4	1
161	Prognostic significance of circulating plasma cells by multi-parametric flow cytometry in light chain amyloidosis. <i>Leukemia</i> , 2018, 32, 1421-1426.	7.2	8
162	Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria. <i>Leukemia</i> , 2018, 32, 2240-2249.	7.2	64

#	ARTICLE	IF	CITATIONS
163	Fifty-Year Incidence of Waldenström Macroglobulinemia in Olmsted County, Minnesota, From 1961 Through 2010: A Population-Based Study With Complete Case Capture and Hematopathologic Review. Mayo Clinic Proceedings, 2018, 93, 739-746.	3.0	29
164	Time to plateau as a predictor of survival in newly diagnosed multiple myeloma. American Journal of Hematology, 2018, 93, 889-894.	4.1	14
165	Analysis of Clinical Factors and Outcomes Associated with Nonuse of Collected Peripheral Blood Stem Cells for Autologous Stem Cell Transplants in Transplant-Eligible Patients with Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2018, 24, 2127-2132.	2.0	21
166	Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia. Annals of Hematology, 2018, 97, 1417-1425.	1.8	71
167	Treatment approaches and outcomes in plasmacytomas: analysis using a national dataset. Leukemia, 2018, 32, 1414-1420.	7.2	20
168	Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance. Leukemia, 2018, 32, 1811-1815.	7.2	28
169	Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance. New England Journal of Medicine, 2018, 378, 241-249.	27.0	392
170	A role for bone turnover markers Î²-CrossLaps (CTX) and amino-terminal propeptide of type I collagen (PINP) as potential indicators for disease progression from MGUS to multiple myeloma. Leukemia and Lymphoma, 2018, 59, 2431-2438.	1.3	10
171	Impact of prior melphalan exposure on stem cell collection in light chain amyloidosis. Bone Marrow Transplantation, 2018, 53, 326-333.	2.4	4
172	Reply to Castillo et al.. American Journal of Hematology, 2018, 93, E71-E73.	4.1	3
173	Laboratory testing for monoclonal gammopathies: Focus on monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Clinical Biochemistry, 2018, 51, 38-47.	1.9	43
174	Risk of melanoma in patients with multiple myeloma: A Surveillance, Epidemiology, and End Results population-based study. Journal of the American Academy of Dermatology, 2018, 78, 621-623.	1.2	9
175	Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myeloma. American Journal of Hematology, 2018, 93, 179-186.	4.1	49
176	MYD88 mutation status does not impact overall survival in Waldenström macroglobulinemia. American Journal of Hematology, 2018, 93, 187-194.	4.1	57
177	Impact of involved free light chain (FLC) levels in patients achieving normal FLC ratio after initial therapy in light chain amyloidosis (AL). American Journal of Hematology, 2018, 93, 17-22.	4.1	11
178	Role of Bone-Modifying Agents in Multiple Myeloma: American Society of Clinical Oncology Clinical Practice Guideline Update. Journal of Clinical Oncology, 2018, 36, 812-818.	1.6	85
179	Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma. Blood Cancer Journal, 2018, 8, 116.	6.2	64
180	Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome. Blood Cancer Journal, 2018, 8, 125.	6.2	29

#	ARTICLE	IF	CITATIONS
181	Utility and prognostic value of ¹⁸ F- ¹⁸ F-DG positron emission tomography-computed tomography scans in patients with newly diagnosed multiple myeloma. American Journal of Hematology, 2018, 93, 1518-1523.	4.1	19
182	Defining Lymphoplasmacytic Lymphoma. American Journal of Clinical Pathology, 2018, 150, 168-176.	0.7	5
183	Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications. Blood, 2018, 132, 1478-1485.	1.4	173
184	Serum free light chain measurements to reduce 24-h urine monitoring in patients with multiple myeloma with measurable urine monoclonal protein. American Journal of Hematology, 2018, 93, 1207-1210.	4.1	3
185	Independent Prognostic Value of Stroke Volume Index in Patients With Immunoglobulin Light Chain Amyloidosis. Circulation: Cardiovascular Imaging, 2018, 11, e006588.	2.6	51
186	Predictors of symptomatic hyperviscosity in Waldenström macroglobulinemia. American Journal of Hematology, 2018, 93, 1384-1393.	4.1	24
187	Staging Systems for Newly Diagnosed Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation: The Revised International Staging System Shows the Most Differentiation between Groups. Biology of Blood and Marrow Transplantation, 2018, 24, 2443-2449.	2.0	11
188	MASS-IFIX may allow identification of patients at risk for light chain amyloidosis before the onset of symptoms. American Journal of Hematology, 2018, 93, E368-E370.	4.1	34
189	Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. Blood Cancer Journal, 2018, 8, 59.	6.2	171
190	IgM Associated Light Chain (AL) Amyloidosis: Delineating Disease Biology with Clinical, Genomic and Bone Marrow Morphological Features. Blood, 2018, 132, 4460-4460.	1.4	1
191	Daratumumab-based therapies in patients with AL amyloidosis.. Journal of Clinical Oncology, 2018, 36, 8053-8053.	1.6	2
192	Utility and prognostic value of 18F-FDG PET/CT scan in patients with newly diagnosed multiple myeloma.. Journal of Clinical Oncology, 2018, 36, 8023-8023.	1.6	0
193	Natural history of del53 multiple myeloma.. Journal of Clinical Oncology, 2018, 36, e20017-e20017.	1.6	0
194	Predictors of disease progression in smoldering Waldenström macroglobulinemia.. Journal of Clinical Oncology, 2018, 36, 7571-7571.	1.6	0
195	Duration of complete response (DurCR) impacts overall survival (OS) in multiple myeloma (MM).. Journal of Clinical Oncology, 2018, 36, 8045-8045.	1.6	0
196	Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy.. Journal of Clinical Oncology, 2018, 36, 8030-8030.	1.6	0
197	Long-Term Survivorship with Active Multiple Myeloma. Blood, 2018, 132, 1912-1912.	1.4	0
198	Comparative Analysis of Staging Systems in AL Amyloidosis. Blood, 2018, 132, 3228-3228.	1.4	0

#	ARTICLE	IF	CITATIONS
199	Treatment Facility Volume and Outcomes in Waldenstrom Macroglobulinemia. Blood, 2018, 132, 622-622.	1.4	1
200	Depth of Response in Waldenstrom Macroglobulinemia. Blood, 2018, 132, 4141-4141.	1.4	2
201	Early Prediction of Treatment Response in Newly Diagnosed Multiple Myeloma. Blood, 2018, 132, 3159-3159.	1.4	0
202	Prognostic Significance of Early Immune Reconstitution in Newly Diagnosed Multiple Myeloma. Blood, 2018, 132, 3158-3158.	1.4	0
203	Impact of Acquired Del(17p) in Patients with Multiple Myeloma. Blood, 2018, 132, 4449-4449.	1.4	0
204	Long-Term AL Amyloidosis Survivors Among Non-Selected Referral Population. Blood, 2018, 132, 3226-3226.	1.4	0
205	Ibrutinib Therapy in Patients with Waldenstrom Macroglobulinemia: Outcomes Outside of Clinical Trial Setting. Blood, 2018, 132, 1606-1606.	1.4	1
206	Expected Survival in Patients with Smoldering Multiple Myeloma and Multiple Myeloma. Blood, 2018, 132, 4497-4497.	1.4	0
207	Development of Thrombocytopenia and Survival Outcomes in Newly Diagnosed Multiple Myeloma. Blood, 2018, 132, 1902-1902.	1.4	1
208	Prognostic Restaging at the Time of 2nd-Line Therapy in Patients with AL Amyloidosis. Blood, 2018, 132, 5594-5594.	1.4	0
209	Optimizing Deep Response Assessment for AL Amyloidosis Using Involved Free Light Chain Level at End of Therapy. Blood, 2018, 132, 3227-3227.	1.4	0
210	Plasma Cell Disorders in Patients with Age-Related Transthyretin (ATTRwt) Amyloidosis. Blood, 2018, 132, 5610-5610.	1.4	0
211	Immune System Profiling of Waldenstrom Macroglobulinemia (WM) and Immunoglobulin M Monoclonal Gammopathy of Undetermined Significance (IgM MGUS) Using Mass Cytometry (CyTOF). Blood, 2018, 132, 4138-4138.	1.4	0
212	Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL). Blood, 2018, 132, 3268-3268.	1.4	0
213	Impact of MYD88L265P mutation Status on Histological Transformation of Waldenstrom Macroglobulinemia. Blood, 2018, 132, 2884-2884.	1.4	1
214	Characterization of Exceptional Responders to Autologous Stem Cell Transplantation in Multiple Myeloma. Blood, 2018, 132, 4615-4615.	1.4	0
215	Plasma Cell Proliferative Index Is an Independent Predictor of Progression in Smoldering Multiple Myeloma. Blood, 2018, 132, 3160-3160.	1.4	2
216	Prognosis of Patients with Waldenstrom Macroglobulinemia: A Simplified Model. Blood, 2018, 132, 4152-4152.	1.4	1

#	ARTICLE	IF	CITATIONS
217	Patient-Reported Outcome Driven Case Management System for Hematology – a Prospective Study. Blood, 2018, 132, 719-719.	1.4	1
218	Overuse of organ biopsies in immunoglobulin light chain amyloidosis (AL): the consequence of failure of early recognition. Annals of Medicine, 2017, 49, 545-551.	3.8	45
219	Hematology patient reported symptom screen to assess quality of life for AL amyloidosis. American Journal of Hematology, 2017, 92, 435-440.	4.1	16
220	The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first-line treatment. Blood, 2017, 129, 82-87.	1.4	50
221	Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. Blood, 2017, 129, 2111-2119.	1.4	249
222	High prevalence of monoclonal gammopathy among patients with warm autoimmune hemolytic anemia. American Journal of Hematology, 2017, 92, E164-E166.	4.1	5
223	Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 40-41.	3.0	4
224	Immunoparesis status in AL amyloidosis at diagnosis affects response and survival by regimen type. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 44-45.	3.0	1
225	The prognostic significance of polyclonal bone marrow plasma cells in patients with relapsing multiple myeloma. American Journal of Hematology, 2017, 92, E507-E512.	4.1	5
226	Clinical presentation and outcomes of patients with type 1 monoclonal cryoglobulinemia. American Journal of Hematology, 2017, 92, 668-673.	4.1	75
227	Therapy for Relapsed Multiple Myeloma. Mayo Clinic Proceedings, 2017, 92, 578-598.	3.0	115
228	Treatment patterns and outcome following initial relapse or refractory disease in patients with systemic light chain amyloidosis. American Journal of Hematology, 2017, 92, 549-554.	4.1	24
229	Diagnosis and Management of Waldenström Macroglobulinemia. JAMA Oncology, 2017, 3, 1257.	7.1	110
230	Elevation of serum lactate dehydrogenase in <scp>AL</scp> amyloidosis reflects tissue damage and is an adverse prognostic marker in patients not eligible for stem cell transplantation. British Journal of Haematology, 2017, 178, 888-895.	2.5	15
231	Multiple myeloma. Nature Reviews Disease Primers, 2017, 3, 17046.	30.5	812
232	Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenström macroglobulinemia. British Journal of Haematology, 2017, 179, 98-105.	2.5	25
233	Efficacy of daratumumab-based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials. American Journal of Hematology, 2017, 92, 1146-1155.	4.1	25
234	Predictors of early treatment failure following initial therapy for systemic immunoglobulin light-chain amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 183-188.	3.0	4

#	ARTICLE	IF	CITATIONS
235	Natural history of amyloidosis isolated to fat and bone marrow aspirate. British Journal of Haematology, 2017, 179, 170-172.	2.5	10
236	Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis. Mayo Clinic Proceedings, 2017, 92, 908-917.	3.0	72
237	Daratumumab-based combination therapies (DCT) in heavily-pretreated patients (pts) with relapsed and/or refractory multiple myeloma (RRMM).. Journal of Clinical Oncology, 2017, 35, 8038-8038.	1.6	1
238	Factors predicting organ response in light chain amyloidosis (AL).. Journal of Clinical Oncology, 2017, 35, 8048-8048.	1.6	1
239	Natural history of t(11;14) multiple myeloma (MM).. Journal of Clinical Oncology, 2017, 35, 8014-8014.	1.6	1
240	The use of proteasome inhibitors among patients with POEMS syndrome.. Journal of Clinical Oncology, 2017, 35, e19530-e19530.	1.6	0
241	Outcomes according to involved free light chain (FLC) levels in patients with normal FLC ratio after initial therapy in light chain amyloidosis (AL).. Journal of Clinical Oncology, 2017, 35, 8049-8049.	1.6	0
242	Risk stratification by detection of clonal circulating plasma cells (CPCs) by multi-parametric flow cytometry (MFC) in light chain amyloidosis (AL).. Journal of Clinical Oncology, 2017, 35, 8047-8047.	1.6	0
243	Overuse of organ biopsies in immunoglobulin light chain (AL) amyloidosis: The consequence of failure of early recognition.. Journal of Clinical Oncology, 2017, 35, e19532-e19532.	1.6	0
244	The impact of body mass index on the risk of early progression of smoldering multiple myeloma to symptomatic myeloma.. Journal of Clinical Oncology, 2017, 35, 8032-8032.	1.6	0
245	Comprehensive Assessment of M-Proteins Using Nanobody Enrichment Coupled to MALDI-TOF Mass Spectrometry. Clinical Chemistry, 2016, 62, 1334-1344.	3.2	122
246	Induction therapy preâ€autologous stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evaluation. American Journal of Hematology, 2016, 91, 984-988.	4.1	45
247	Immunoparesis status in immunoglobulin light chain amyloidosis at diagnosis affects response and survival by regimen type. Haematologica, 2016, 101, 1102-1109.	3.5	9
248	The prognostic significance of CD45 expression by clonal bone marrow plasma cells in patients with newly diagnosed multiple myeloma. Leukemia Research, 2016, 44, 32-39.	0.8	22
249	Clinical Features and Treatment Outcomes of Patients With Necrobiotic Xanthogranuloma Associated With Monoclonal Gammopathies. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 447-452.	0.4	24
250	Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood, 2016, 127, 2955-2962.	1.4	686
251	Myelomatous Involvement of the Central Nervous System. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 644-654.	0.4	38
252	Systemic Immunoglobulin Light Chain Amyloidosisâ€Associated Myopathy: Presentation, Diagnostic Pitfalls, and Outcome. Mayo Clinic Proceedings, 2016, 91, 1354-1361.	3.0	43

#	ARTICLE	IF	CITATIONS
253	Prognostic factors and indications for treatment of Waldenström's Macroglobulinemia. Best Practice and Research in Clinical Haematology, 2016, 29, 179-186.	1.7	12
254	Progress in Myeloma – A Monoclonal Breakthrough. New England Journal of Medicine, 2016, 375, 1390-1392.	27.0	36
255	Outcomes of patients with renal monoclonal immunoglobulin deposition disease. American Journal of Hematology, 2016, 91, 1123-1128.	4.1	76
256	Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR Analysis. Biology of Blood and Marrow Transplantation, 2016, 22, 1893-1899.	2.0	34
257	Long-term outcome of patients with POEMS syndrome: An update of the Mayo Clinic experience. American Journal of Hematology, 2016, 91, 585-589.	4.1	57
258	Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System. Journal of the American College of Cardiology, 2016, 68, 1014-1020.	2.8	460
259	N-terminal fragment of the type B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma. American Journal of Hematology, 2016, 91, 1129-1134.	4.1	71
260	International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncology, The, 2016, 17, e328-e346.	10.7	1,866
261	Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia. British Journal of Haematology, 2016, 175, 77-86.	2.5	61
262	Clinical characteristics and outcomes in biclonal gammopathies. American Journal of Hematology, 2016, 91, 473-475.	4.1	30
263	Predictors of Early Relapse Following Initial Therapy for Systemic Immunoglobulin Light Chain Amyloidosis. Blood, 2016, 128, 2082-2082.	1.4	1
264	Bendamustine and Rituximab Versus Dexamethasone, Rituximab and Cyclophosphamide in Patients with Waldenstrom Macroglobulinemia (WM). Blood, 2016, 128, 2968-2968.	1.4	4
265	Dexamethasone, Rituximab and Cyclophosphamide (DRC) As Salvage Therapy for Waldenstrom Macroglobulinemia. Blood, 2016, 128, 2972-2972.	1.4	2
266	Clinical Presentation and Outcomes of Patients with Light Chain Amyloidosis Who Have Non-Evaluable Free Light Chains at Diagnosis. Blood, 2016, 128, 3272-3272.	1.4	1
267	Bortezomib Versus Non-Bortezomib Based Treatment for Transplant Ineligible Patients with Light Chain Amyloidosis. Blood, 2016, 128, 3317-3317.	1.4	3
268	Efficacy of Carfilzomib (K), Pomalidomide (P), and Dexamethasone (d) in Heavily Pretreated Patients with Relapsed/ Refractory Multiple Myeloma (RRMM) in a Real World Setting. Blood, 2016, 128, 3337-3337.	1.4	5
269	Effect of Standard Dose Versus Risk Adapted Melphalan Conditioning on Outcomes in Systemic AL Amyloidosis Patients Undergoing Frontline Autologous Stem Cell Transplant Based on Revised Mayo Stage. Blood, 2016, 128, 4627-4627.	1.4	1
270	Evolving changes in M-protein (M), quantitative involved immunoglobulin (Ig), and hemoglobin (Hb) to identify patients (pts) with ultra high-risk smoldering multiple myeloma (UHR-SMM).. Journal of Clinical Oncology, 2016, 34, 8004-8004.	1.6	3

#	ARTICLE	IF	CITATIONS
271	Quantification of circulating clonal plasma cells (cPCs) via multiparametric flow cytometry (MFC) to identify patients with smoldering multiple myeloma (SMM) at high risk of progression.. Journal of Clinical Oncology, 2016, 34, 8015-8015.	1.6	1
272	Long term outcomes of cardiac transplant for immunoglobulin light chain amyloidosis: The Mayo Clinic experience. World Journal of Transplantation, 2016, 6, 380.	1.6	56
273	Prevalence and survival of smoldering multiple myeloma in the US: Analysis using a national dataset.. Journal of Clinical Oncology, 2016, 34, 8035-8035.	1.6	0
274	Dexamethasone, rituximab and cyclophosphamide (DRC) in relapsed/refractory (R/R) and treatment naïve (TN) Waldenström macroglobulinemia (WM).. Journal of Clinical Oncology, 2016, 34, 7552-7552.	1.6	1
275	Type 1 monoclonal cryoglobulinemia: Clinical presentation and outcomes.. Journal of Clinical Oncology, 2016, 34, 8062-8062.	1.6	0
276	Immunoparesis in newly diagnosed AL amyloidosis as a marker for response and survival.. Journal of Clinical Oncology, 2016, 34, 8016-8016.	1.6	0
277	Prognostic Implications of Multiple Cytogenetic High-Risk Abnormalities in Patients with Newly Diagnosed Multiple Myeloma. Blood, 2016, 128, 5615-5615.	1.4	0
278	Thyroid Functional Abnormalities in Newly Diagnosed AL Amyloidosis: Frequency and Influence By Type of Organ Involvement and Disease Burden. Blood, 2016, 128, 3273-3273.	1.4	0
279	Changes in Uninvolved Immunoglobulins during Multiple Myeloma Therapy. Blood, 2016, 128, 3251-3251.	1.4	0
280	Concomitant Myeloproliferative Disorders (MPD) and Amyloidosis. Blood, 2016, 128, 5480-5480.	1.4	1
281	Survival Trends in Young Patients with Waldenstrom Macroglobulinemia: Over 5 Decades of Experience. Blood, 2016, 128, 1810-1810.	1.4	0
282	The Prognostic Significance of Polyclonal Bone Marrow Plasma Cells in Patients with Actively Relapsing Multiple Myeloma. Blood, 2016, 128, 1194-1194.	1.4	0
283	Fluorescence in-Situ Hybridization (FISH) Analysis in Untreated AL Amyloidosis Has an Independent Prognostic Impact By Abnormality Type and Treatment Category. Blood, 2016, 128, 3269-3269.	1.4	0
284	Treatment Patterns and Outcomes Following Initial Relapse in Patients with Relapsed Systemic Immunoglobulin Light Chain Amyloidosis. Blood, 2016, 128, 3338-3338.	1.4	0
285	Predicting Poor Overall Survival in Patients with Newly Diagnosed Multiple Myeloma and Standard-Risk Cytogenetics Treated with Novel Agents. Blood, 2016, 128, 3255-3255.	1.4	0
286	Outcome of Very Young (≤ 40 years) Patients with Immunoglobulin Light Chain Amyloidosis (AL): A Case Control Study. Blood, 2016, 128, 5576-5576.	1.4	0
287	Impact of Melphalan-Based Chemotherapy on Stem Cell Collection in Patients with Light Chain Amyloidosis. Blood, 2016, 128, 2187-2187.	1.4	0
288	Predictors of early response to initial therapy in patients with newly diagnosed symptomatic multiple myeloma. American Journal of Hematology, 2015, 90, 888-891.	4.1	18

#	ARTICLE	IF	CITATIONS
289	Outcomes of primary refractory multiple myeloma and the impact of novel therapies. American Journal of Hematology, 2015, 90, 981-985.	4.1	38
290	Evidence Against Routine Testing of Patients With Functional Gastrointestinal Disorders for Celiac Disease: A Population-based Study. Clinical Gastroenterology and Hepatology, 2015, 13, 1937-1943.	4.4	23
291	Clinical and prognostic differences among patients with light chain deposition disease, myeloma cast nephropathy and both. Leukemia and Lymphoma, 2015, 56, 3357-3364.	1.3	36
292	Elevation of Serum Immunoglobulin Free Light Chains During the Preclinical Period of Rheumatoid Arthritis. Journal of Rheumatology, 2015, 42, 181-187.	2.0	20
293	Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis. American Journal of Hematology, 2015, 90, 181-186.	4.1	76
294	Diagnosis of monoclonal gammopathy of renal significance. Kidney International, 2015, 87, 698-711.	5.2	339
295	Monitoring IgA Multiple Myeloma: Immunoglobulin Heavy/Light Chain Assays. Clinical Chemistry, 2015, 61, 360-367.	3.2	57
296	Clinical course and prognosis of nonsecretory multiple myeloma. European Journal of Haematology, 2015, 95, 57-64.	2.2	50
297	Hematologic Characteristics of Proliferative Glomerulonephritides With Nonorganized Monoclonal Immunoglobulin Deposits. Mayo Clinic Proceedings, 2015, 90, 587-596.	3.0	92
298	Treatment of Immunoglobulin Light Chain Amyloidosis. Mayo Clinic Proceedings, 2015, 90, 1054-1081.	3.0	106
299	Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma. JAMA Oncology, 2015, 1, 174.	7.1	8
300	Soluble suppression of tumorigenicity 2 (sST ²), but not galactin-3, adds to prognostication in patients with systemic AL amyloidosis independent of NT-proBNP and troponin T. American Journal of Hematology, 2015, 90, 524-528.	4.1	31
301	Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study. Journal of Clinical Oncology, 2015, 33, 3741-3749.	1.6	163
302	Impact of Pretransplant Therapy and Depth of Disease Response before Autologous Transplantation for Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2015, 21, 335-341.	2.0	64
303	In Patients with Light-Chain (AL) Amyloidosis Myocardial Contraction Fraction (MCF) Is a Simple, but Powerful Prognostic Measure That Can be Calculated from a Standard Echocardiogram (ECHO). Blood, 2015, 126, 1774-1774.	1.4	6
304	Necrobiotic Xanthogranuloma (NXG) Associated with Monoclonal Gammopathies (MG): Clinical Features and Treatment Outcomes. Blood, 2015, 126, 1830-1830.	1.4	1
305	Presentation and Outcomes of Localized Amyloidosis: The Mayo Clinic Experience. Blood, 2015, 126, 4197-4197.	1.4	5
306	VLX1570, a First in Class Dub Inhibitor, Modulates BCR Signaling and CXCR4 Expression and Demonstrates Significant In Vivo Antitumor Activity in a Murine Model of Human Waldenstrom Macroglobulinemia. Blood, 2015, 126, 703-703.	1.4	4

#	ARTICLE	IF	CITATIONS
307	N-Terminal Fragment of the Type-B Natriuretic Peptide (NT-proBNP) Is a Prognostic Factor for Overall Survival in Newly Diagnosed Patients with Multiple Myeloma (MM). <i>Blood</i> , 2015, 126, 3292-3292.	1.4	0
308	AL Amyloidosis and Patient Reported Quality of Life. <i>Blood</i> , 2015, 126, 3317-3317.	1.4	0
309	Occurrence and Prognostic Significance of Cytogenetic Evolution in Patients with Multiple Myeloma. <i>Blood</i> , 2015, 126, 4176-4176.	1.4	0
310	Natural History of Amyloidosis Isolated to Fat and Bone Marrow Aspirate. <i>Blood</i> , 2015, 126, 5303-5303.	1.4	0
311	Immunoglobulin light chain amyloidosis is diagnosed late in patients with preexisting plasma cell dyscrasias. <i>American Journal of Hematology</i> , 2014, 89, 1051-1054.	4.1	32
312	Protein Electrophoresis and Immunofixation for the Diagnosis of Monoclonal Gammopathies. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 2160.	7.4	3
313	A Structurally Distinct Human Mycoplasma Protein that Generically Blocks Antigen-Antibody Union. <i>Science</i> , 2014, 343, 656-661.	12.6	85
314	Yield of Noncardiac Biopsy for the Diagnosis of Transthyretin Cardiac Amyloidosis. <i>American Journal of Cardiology</i> , 2014, 113, 1723-1727.	1.6	112
315	Outcomes and treatments of patients with immunoglobulin light chain amyloidosis who progress or relapse postautologous stem cell transplant. <i>European Journal of Haematology</i> , 2014, 92, 485-490.	2.2	23
316	Clinical course of light-chain smouldering multiple myeloma (idiopathic Bence Jones proteinuria): a retrospective cohort study. <i>Lancet Haematology</i> , 2014, 1, e28-e36.	4.6	40
317	International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. <i>Lancet Oncology</i> , 2014, 15, e538-e548.	10.7	3,343
318	Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma. <i>Hematology/Oncology Clinics of North America</i> , 2014, 28, 775-790.	2.2	35
319	Remission of Disseminated Cancer After Systemic Oncolytic Virotherapy. <i>Mayo Clinic Proceedings</i> , 2014, 89, 926-933.	3.0	240
320	Hematopoietic Cell Transplant Comorbidity Index Is Predictive of Survival after Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 402-408.e1.	2.0	98
321	Trends in survival of patients with primary plasma cell leukemia: a population-based analysis. <i>Blood</i> , 2014, 124, 907-912.	1.4	111
322	Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013. <i>Mayo Clinic Proceedings</i> , 2013, 88, 360-376.	3.0	440
323	Immunoglobulin M Monoclonal Gammopathy of Undetermined Significance and Smoldering Waldenström Macroglobulinemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 184-186.	0.4	17
324	Coexistent Multiple Myeloma or Increased Bone Marrow Plasma Cells Define Equally High-Risk Populations in Patients With Immunoglobulin Light Chain Amyloidosis. <i>Journal of Clinical Oncology</i> , 2013, 31, 4319-4324.	1.6	193

#	ARTICLE	IF	CITATIONS
325	Implantable Cardioverter Defibrillators in Patients with Cardiac Amyloidosis. Journal of Cardiovascular Electrophysiology, 2013, 24, 793-798.	1.7	148
326	How I treat monoclonal gammopathy of renal significance (MGRS). Blood, 2013, 122, 3583-3590.	1.4	259
327	Survival Outcomes Of Very Young (<40 years) Myeloma Patients. Blood, 2013, 122, 2136-2136.	1.4	3
328	Soluble ST2 (sST2) Is a Novel Valuable Prognostic Marker Among Patients With Immunoglobulin Light Chain (AL) Amyloidosis. Blood, 2013, 122, 3095-3095.	1.4	1
329	Therapy Related MDS/AML In Multiple Myeloma Patients In The Era Of Novel Agents. Blood, 2013, 122, 3117-3117.	1.4	2
330	Myelomatous Involvement Of The Central Nervous System: Mayo Clinic Experience. Blood, 2013, 122, 3119-3119.	1.4	3
331	Lenalidomide Maintenance Therapy In Multiple Myeloma: A Meta-Analysis Of Randomized Trials. Blood, 2013, 122, 407-407.	1.4	12
332	Long Term Response To Lenalidomide With and Without Continuous Therapy Among Patients With Newly Diagnosed Multiple Myeloma. Blood, 2013, 122, 3209-3209.	1.4	0
333	Revised Prognostic Staging System for Light Chain Amyloidosis Incorporating Cardiac Biomarkers and Serum Free Light Chain Measurements. Journal of Clinical Oncology, 2012, 30, 989-995.	1.6	837
334	Targeted therapy of multiple myeloma. Hematology, 2012, 17, s125-s128.	1.5	8
335	Progression in smoldering Waldenström macroglobulinemia: long-term results. Blood, 2012, 119, 4462-4466.	1.4	113
336	Incidence of Monoclonal Gammopathy of Undetermined Significance and Estimation of Duration Before First Clinical Recognition. Mayo Clinic Proceedings, 2012, 87, 1071-1079.	3.0	94
337	Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. Blood, 2012, 120, 4292-4295.	1.4	447
338	Continued Improvement in Survival in Multiple Myeloma and the Impact of Novel Agents. Blood, 2012, 120, 3972-3972.	1.4	7
339	Survival After Second, Third, and Fourth Line Therapy Better Than Expected in Patients with Previously Treated AL Amyloidosis Who Were Not Transplant Candidates At Diagnosis.. Blood, 2012, 120, 946-946.	1.4	1
340	Outcomes of Patients with POEMS Syndrome Treated Initially with Radiation. Blood, 2012, 120, 448-448.	1.4	0
341	Development of Myelodysplastic Syndrome and Acute Leukemias in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS): A Population-Based Study of 17,315 Patients. Blood, 2012, 120, 934-934.	1.4	0
342	Idiopathic Bence Jones Proteinuria (Smoldering Monoclonal Light-Chain Proteinuria): Clinical Course and Prognosis. Blood, 2012, 120, 1861-1861.	1.4	2

#	ARTICLE	IF	CITATIONS
343	Treatment Trade-Offs in Myeloma: a Survey of Consecutive Patients. Blood, 2012, 120, 2059-2059.	1.4	0
344	Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood, 2011, 117, 4701-4705.	1.4	377
345	Recent Improvements in Survival in Primary Systemic Amyloidosis and the Importance of an Early Mortality Risk Score. Mayo Clinic Proceedings, 2011, 86, 12-18.	3.0	164
346	Role of Maintenance Therapy After Autologous Stem Cell Transplant for Multiple Myeloma: Lessons for Cancer Therapy. Mayo Clinic Proceedings, 2011, 86, 419-420.	3.0	10
347	The definition of IgM multiple myeloma. American Journal of Hematology, 2011, 86, 718-719.	4.1	1
348	History of Multiple Myeloma. Recent Results in Cancer Research, 2011, 183, 3-23.	1.8	13
349	The Utility of High Sensitivity Cardiac Troponin Among Patients with Immunoglobulin Light Chain Amyloidosis. Blood, 2011, 118, 2887-2887.	1.4	1
350	Factors Predicting Early Mortality in Patients with Newly Diagnosed Multiple Myeloma,. Blood, 2011, 118, 3981-3981.	1.4	3
351	Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features. Blood, 2010, 116, 5126-5129.	1.4	146
352	Systemic AL amyloidosis with acquired factor X deficiency: A study of perioperative bleeding risk and treatment outcomes in 60 patients. American Journal of Hematology, 2010, 85, 171-173.	4.1	75
353	Monoclonal gammopathy of undetermined significance: a consensus statement. British Journal of Haematology, 2010, 150, 28-38.	2.5	95
354	Advances in the Diagnosis, Classification, Risk Stratification, and Management of Monoclonal Gammopathy of Undetermined Significance: Implications for Recategorizing Disease Entities in the Presence of Evolving Scientific Evidence. Mayo Clinic Proceedings, 2010, 85, 945-948.	3.0	105
355	Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. Lancet, The, 2010, 375, 1721-1728.	13.7	313
356	Screening Panels for Detection of Monoclonal Gammopathies. Clinical Chemistry, 2009, 55, 1517-1522.	3.2	268
357	The treatment of multiple myeloma using vincristine, carmustine, melphalan, cyclophosphamide, and prednisone (VBMCP) alternating with high-dose cyclophosphamide and $\text{IFN-}\alpha$ versus VBMCP. Cancer, 2009, 115, 2155-2164.	4.1	9
358	IgM Monoclonal Gammopathy of Undetermined Significance and Smoldering Waldenström's Macroglobulinemia. Clinical Lymphoma and Myeloma, 2009, 9, 17-18.	1.4	50
359	Treatment of Multiple Myeloma: A Comprehensive Review. Clinical Lymphoma and Myeloma, 2009, 9, 278-288.	1.4	135
360	Improved survival in multiple myeloma and the impact of novel therapies. Blood, 2008, 111, 2516-2520.	1.4	2,022

#	ARTICLE	IF	CITATIONS
361	Multiple myeloma. Blood, 2008, 111, 2962-2972.	1.4	759
362	Response Duration with Initial Therapy Is a Major Predictor of Overall Survival in Multiple Myeloma: Analysis from Multiple Phase III ECOG Clinical Trials. Blood, 2008, 112, 5129-5129.	1.4	3
363	Survival in Patients with Newly Diagnosed Myeloma Undergoing Therapy with Lenalidomide and Dexamethasone: Impact of High-Risk Cytogenetic Risk Status on Outcome. Blood, 2008, 112, 95-95.	1.4	3
364	Increased Risk of Monoclonal Gammopathy in First-Degree Relatives of Patients with Multiple Myeloma or Monoclonal Gammopathy of Undetermined Significance.. Blood, 2008, 112, 1672-1672.	1.4	0
365	Mechanisms of the Formation of Multinuclear Malignant Plasma Cells in the Novel AL/MM Human Cell Lines, ALMC-1 and ALMC-2: Implications for Tumor Cell Growth Control.. Blood, 2008, 112, 1707-1707.	1.4	0
366	Clinical Course and Prognosis of Smoldering (Asymptomatic) Waldenstrom's Macroglobulinemia. Blood, 2008, 112, 2709-2709.	1.4	6
367	Epidemiology of the plasma-cell disorders. Best Practice and Research in Clinical Haematology, 2007, 20, 637-664.	1.7	109
368	Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma. New England Journal of Medicine, 2007, 356, 2582-2590.	27.0	740
369	Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma. Hematology/Oncology Clinics of North America, 2007, 21, 1093-1113.	2.2	49
370	Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: emphasis on risk factors for progression. British Journal of Haematology, 2007, 139, 730-743.	2.5	98
371	Activation of MYC Pathway Is a Unifying Pathological Event in the Progression from Monoclonal Gammopathy of Undetermined Significance (MGUS) to Myeloma (MM).. Blood, 2007, 110, 241-241.	1.4	1
372	14q32 Abnormalities and 13q Deletions Are Common in Primary Systemic Amyloidosis Using Cytoplasmic Immunoglobulin Fluorescence In Situ Hybridization (cIg-FISH).. Blood, 2007, 110, 2477-2477.	1.4	1
373	Prevalence of Post-Transplant Lymphoproliferative Disorder with Monoclonal Gammopathy of Unknown Significance in Patients Undergoing Kidney Transplantation.. Blood, 2007, 110, 4778-4778.	1.4	0
374	Increased Cytotoxic T-Cell Infiltrates in the Bone Marrow Is an Independent Adverse Prognostic Factor in Patients with Newly Diagnosed Multiple Myeloma.. Blood, 2007, 110, 1492-1492.	1.4	0
375	Engraftment Syndrome Is Common in Patients with POEMS Syndrome Undergoing PBSCT.. Blood, 2007, 110, 2995-2995.	1.4	0
376	Pre Transplantation MGUS and Transformation to Multiple Myeloma in Kidney Transplantation: A Single Center Experience.. Blood, 2007, 110, 4779-4779.	1.4	0
377	Treatment of multiple myeloma: An emphasis on new developments. Annals of Medicine, 2006, 38, 111-115.	3.8	15
378	Prevalence of Monoclonal Gammopathy of Undetermined Significance. New England Journal of Medicine, 2006, 354, 1362-1369.	27.0	1,135

#	ARTICLE	IF	CITATIONS
379	Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. <i>Blood</i> , 2006, 107, 3378-3383.	1.4	230
380	Monoclonal gammopathy of undetermined significance. <i>British Journal of Haematology</i> , 2006, 134, 573-589.	2.5	191
381	Idiopathic Bence Jones Proteinuria: Clinical Course and Prognosis.. <i>Blood</i> , 2006, 108, 3493-3493.	1.4	1
382	Natural History, Genetic Aberrations and Survival Distinguish Primary Plasma Cell Leukemia from Multiple Myeloma with Leukemic Transformation.. <i>Blood</i> , 2006, 108, 3587-3587.	1.4	0
383	International Staging System for Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2005, 23, 3412-3420.	1.6	2,404
384	Monoclonal Gammopathy of Undetermined Significance. <i>Clinical Lymphoma and Myeloma</i> , 2005, 6, 102-114.	1.4	43
385	Monoclonal gammopathies of undetermined significance. <i>Best Practice and Research in Clinical Haematology</i> , 2005, 18, 689-707.	1.7	31
386	Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. <i>Blood</i> , 2005, 106, 812-817.	1.4	557
387	The Natural History of Smoldering (Asymptomatic) Multiple Myeloma.. <i>Blood</i> , 2005, 106, 3396-3396.	1.4	9
388	Combination Therapy with Lenalidomide Plus Dexamethasone (Rev/Dex) for Newly Diagnosed Myeloma.. <i>Blood</i> , 2005, 106, 781-781.	1.4	5
389	Cancer/Testis Antigen Profiling in Multiple Myeloma Define a Cohort of Patients with Poor Prognosis Regardless of Genetic Subtypes.. <i>Blood</i> , 2005, 106, 3381-3381.	1.4	0
390	Response to Rituximab in Type II Cryoglobulinemia.. <i>Blood</i> , 2005, 106, 3499-3499.	1.4	0
391	The t(4;14) Is Present in Patients with Early Stage Plasma Cell Proliferative Disorders Including MGUS and Smoldering Multiple Myeloma (SMM).. <i>Blood</i> , 2005, 106, 1545-1545.	1.4	2
392	Serum Cardiac Troponins and N-Terminal Pro-Brain Natriuretic Peptide: A Staging System for Primary Systemic Amyloidosis. <i>Journal of Clinical Oncology</i> , 2004, 22, 3751-3757.	1.6	774
393	Incidence of multiple myeloma in Olmsted County, Minnesota. <i>Cancer</i> , 2004, 101, 2667-2674.	4.1	178
394	Multiple Myeloma. <i>New England Journal of Medicine</i> , 2004, 351, 1860-1873.	27.0	1,291
395	Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. <i>Blood</i> , 2004, 104, 1881-1887.	1.4	300
396	Combination Therapy with CC-5013 (Lenalidomide; Revlimidâ„¢) Plus Dexamethasone (Rev/Dex) for Newly Diagnosed Myeloma (MM).. <i>Blood</i> , 2004, 104, 331-331.	1.4	16

#	ARTICLE	IF	CITATIONS
397	Presence of an Abnormal Serum Free Light Ratio Is an Independent Risk Factor for Progression in Monoclonal Gammopathy of Undetermined Significance (MGUS).. Blood, 2004, 104, 3647-3647.	1.4	66
398	Associations of DNA Repair Gene Polymorphisms in XRCC1 and ERCC2 with Clinical Outcome in ECOG Trial E9486.. Blood, 2004, 104, 1475-1475.	1.4	0
399	Comparison of Early and Late Autologous Stem Cell Transplants for Multiple Myeloma: A Single Institution Experience.. Blood, 2004, 104, 928-928.	1.4	0
400	The Mayo Clinic Experience with 66 Patients with Type II Cryoglobulinemia.. Blood, 2004, 104, 1493-1493.	1.4	0
401	B-Lymphocyte Stimulator (BLyS) Is Highly Expressed in Waldenstrom's Macroglobulinemia.. Blood, 2004, 104, 2291-2291.	1.4	1
402	Monoclonal gammopathies of undetermined significance: a review. Immunological Reviews, 2003, 194, 112-139.	6.0	110
403	POEMS Syndrome. Clinical Lymphoma and Myeloma, 2003, 4, 186.	2.1	0
404	Review of 1027 Patients With Newly Diagnosed Multiple Myeloma. Mayo Clinic Proceedings, 2003, 78, 21-33.	3.0	1,904
405	Localized AL amyloidosis of the colon: an unrecognized entity. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2003, 10, 36-41.	3.0	25
406	Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Blood, 2003, 102, 3759-3764.	1.4	279
407	Current Therapy of Multiple Myeloma.. Internal Medicine, 2002, 41, 175-180.	0.7	12
408	A Long-Term Study of Prognosis in Monoclonal Gammopathy of Undetermined Significance. New England Journal of Medicine, 2002, 346, 564-569.	27.0	1,304
409	Primary Localized Amyloidosis of The bladder:: Experience With Dimethyl Sulfoxide Therapy. Journal of Urology, 2002, 168, 1018-1020.	0.4	43
410	Correlation of Serum Immunoglobulin Free Light Chain Quantification with Urinary Bence Jones Protein in Light Chain Myeloma. Clinical Chemistry, 2002, 48, 655-657.	3.2	115
411	Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood, 2002, 100, 1417-1424.	1.4	317
412	MONOCLONAL GAMMOPATHIES OF UNDETERMINED SIGNIFICANCE. Reviews in Clinical and Experimental Hematology, 2002, 6, 225-252.	0.1	26
413	Diagnosis of multiple myeloma. Seminars in Oncology, 2002, 29, 2-4.	2.2	8
414	Henry Bence Jones - physician, chemist, scientist and biographer: A man for all seasons. British Journal of Haematology, 2001, 115, 13-18.	2.5	19

#	ARTICLE	IF	CITATIONS
415	Amyloidosis: a convoluted story. British Journal of Haematology, 2001, 114, 529-538.	2.5	186
416	Methods for estimation of bone marrow plasma cell involvement in myeloma: Predictive value for response and survival in patients undergoing autologous stem cell transplantation. American Journal of Hematology, 2001, 68, 269-275.	4.1	61
417	Update on the Treatment of Multiple Myeloma. Oncologist, 2001, 6, 119-124.	3.7	21
418	Multiple myeloma: an odyssey of discovery. British Journal of Haematology, 2000, 111, 1035-1044.	2.5	2
419	FISH Demonstrates Treatment-Related Chromosome Damage in Myeloid but not Plasma Cells in Primary Systemic Amyloidosis. Leukemia and Lymphoma, 2000, 39, 391-395.	1.3	11
420	Primary Localized Amyloidosis of the Urinary Bladder: A Case Series of 31 Patients. Mayo Clinic Proceedings, 2000, 75, 1264-1268.	3.0	119
421	Prospective Randomized Trial of Melphalan and Prednisone Versus Vincristine, Carmustine, Melphalan, Cyclophosphamide, and Prednisone in the Treatment of Primary Systemic Amyloidosis. Journal of Clinical Oncology, 1999, 17, 262-262.	1.6	77
422	Plasmablastic Morphology Is an Independent Predictor of Poor Survival After Autologous Stem-Cell Transplantation for Multiple Myeloma. Journal of Clinical Oncology, 1999, 17, 1551-1551.	1.6	64
423	Long-Term Survival (10 Years or More) in 30 Patients With Primary Amyloidosis. Blood, 1999, 93, 1062-1066.	1.4	180
424	Clinical Significance of the Translocation (11;14)(q13;q32) in Multiple Myeloma. Leukemia and Lymphoma, 1999, 35, 599-605.	1.3	31
425	VIII International Symposium on Amyloidosis, August 7-11,1998, Rochester, MN. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 1999, 6, 59-62.	3.0	0
426	Guidelines for Clinical and Laboratory Evaluation of Patients With Monoclonal Gammopathies. Archives of Pathology and Laboratory Medicine, 1999, 123, 106-107.	2.5	113
427	Primary systemic amyloidosis with delayed progression to multiple myeloma. , 1998, 82, 1501-1505.		105
428	Primary plasmacytoma at the site of exit wounds after electrical injury. , 1998, 58, 77-79.		8
429	Familial amyloid with a transthyretin leucine 33 mutation presenting with ascites. , 1998, 59, 249-251.		7
430	Detection of monoclonal plasma cells in the peripheral blood of patients with primary amyloidosis. British Journal of Haematology, 1998, 100, 326-327.	2.5	14
431	Multiple myeloma and the translocation t(11;14)(q13;q32): a report on 13 cases. British Journal of Haematology, 1998, 101, 296-301.	2.5	70
432	Chromosomal abnormalities in systemic amyloidosis. British Journal of Haematology, 1998, 103, 704-710.	2.5	49

#	ARTICLE	IF	CITATIONS
433	Multiple Myeloma in Young Patients: Clinical Presentation and Treatment Approach. Leukemia and Lymphoma, 1998, 30, 493-501.	1.3	100
434	Primary systemic amyloidosis with delayed progression to multiple myeloma. Cancer, 1998, 82, 1501-1505.	4.1	3
435	A Trial of Three Regimens for Primary Amyloidosis: Colchicine Alone, Melphalan and Prednisone, and Melphalan, Prednisone, and Colchicine. New England Journal of Medicine, 1997, 336, 1202-1207.	27.0	656
436	Circulating Blood B Cells in Multiple Myeloma: Analysis and Relationship to Circulating Clonal Cells and Clinical Parameters in a Cohort of Patients Entered on the Eastern Cooperative Oncology Group Phase III E9486 Clinical Trial. Blood, 1997, 90, 340-345.	1.4	59
437	Identification of monoclonal proteins in serum: A quantitative comparison of acetate, agarose gel, and capillary electrophoresis. Electrophoresis, 1997, 18, 1775-1780.	2.4	49
438	Multiple myeloma associated with diffuse osteosclerotic bone lesions: A clinical entity distinct from osteosclerotic myeloma (POEMS syndrome)., 1997, 56, 288-293.		54
439	Transthyretin ILE20, a new variant associated with late-onset cardiac amyloidosis. Human Mutation, 1997, 9, 83-85.	2.5	13
440	Circulating Blood B Cells in Multiple Myeloma: Analysis and Relationship to Circulating Clonal Cells and Clinical Parameters in a Cohort of Patients Entered on the Eastern Cooperative Oncology Group Phase III E9486 Clinical Trial. Blood, 1997, 90, 340-345.	1.4	5
441	Development of monoclonal gammopathy precedes the development of Epstein-Barr virus-induced posttransplant lymphoproliferative disorder. Liver Transplantation, 1996, 2, 375-382.	1.8	71
442	Presenting Features and Prognosis in 72 Patients With Multiple Myeloma Who Were Younger Than 40 Years. British Journal of Haematology, 1996, 93, 345-351.	2.5	177
443	Multiple Myeloma: An Overview in 1996. Oncologist, 1996, 1, 315-323.	3.7	5
444	Clinicopathological correlates of CD56 expression in multiple myeloma: a unique entity?. British Journal of Haematology, 1995, 90, 459-461.	2.5	30
445	Serial Studies of Peripheral Blood Myeloma Cells in Patients with Multiple Myeloma: When is the Optimal Time for Stem Cell Harvest?. Leukemia and Lymphoma, 1995, 19, 417-422.	1.3	8
446	MONOCLONAL PROTEINS AND RENAL DISEASE. Annual Review of Medicine, 1994, 45, 71-77.	12.2	35
447	Detection of peripheral blood plasma cells as a predictor of disease course in patients with smouldering multiple myeloma. British Journal of Haematology, 1994, 87, 266-272.	2.5	89
448	IgD monoclonal gammopathy with long-term follow-up. British Journal of Haematology, 1994, 88, 395-396.	2.5	32
449	Expression of shared idiotypes by paraproteins from patients with monoclonal gammopathy of undetermined significance. British Journal of Haematology, 1994, 87, 719-724.	2.5	3
450	Quantitation of circulating peripheral blood plasma cells and their relationship to disease activity in patients with multiple myeloma. Cancer, 1993, 72, 108-113.	4.1	71

#	ARTICLE	IF	CITATIONS
451	Amyloid Localized to Tenosynovium at Carpal Tunnel Release: <i>Immunohistochemical Identification of Amyloid Type</i>. American Journal of Clinical Pathology, 1992, 97, 250-253.	0.7	68
452	Î¼4-heavy chain disease: Presentation as a benign monoclonal gammopathy. American Journal of Hematology, 1992, 40, 56-60.	4.1	43
453	Cranial neuropathy associated with primary amyloidosis. Annals of Neurology, 1991, 29, 451-454.	5.3	52
454	Neuropathy associated with monoclonal gammopathies of undetermined significance. Annals of Neurology, 1991, 30, 54-61.	5.3	219
455	Computed tomography for diagnosis of hepatic rupture in primary systemic amyloidosis. American Journal of Hematology, 1991, 37, 194-196.	4.1	38
456	Speech disorders in systemic amyloidosis. International Journal of Language and Communication Disorders, 1991, 26, 201-206.	1.5	11
457	Amyloid Localized to Tenosynovium at Carpal Tunnel Release: Natural History of 124 Cases. American Journal of Clinical Pathology, 1989, 91, 393-397.	0.7	62
458	Multiple responses of aplastic anemia to low-dose cyclosporine therapy despite development of a myelodysplastic syndrome. American Journal of Hematology, 1989, 32, 226-229.	4.1	19
459	Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. European Journal of Haematology, 1989, 43, 70-75.	2.2	9
460	IgD multiple myeloma: A cure at 21 years. American Journal of Hematology, 1988, 29, 41-43.	4.1	26
461	Prognostic factors in multiple myeloma. Hematological Oncology, 1988, 6, 125-130.	1.7	24
462	Monoclonal Proteins in Chronic Lymphocytic Leukemia. American Journal of Clinical Pathology, 1987, 87, 385-388.	0.7	41
463	Plasma cell leukemia: An evaluation of response to therapy. American Journal of Medicine, 1987, 83, 1062-1068.	1.5	164
464	Synovial fluid analysis for diagnosis of amyloid arthropathy. Arthritis and Rheumatism, 1987, 30, 419-423.	6.7	29
465	Primary amyloidosis (AL) in families. American Journal of Hematology, 1986, 22, 193-198.	4.1	14
466	A monoclonal antibody reactive with a subset of human plasma cells. British Journal of Haematology, 1986, 62, 619-630.	2.5	24
467	A monoclonal antibody reactive with 5-bromo-2-deoxyuridine that does not require DNA denaturation. Cytometry, 1985, 6, 506-512.	1.8	107
468	Worsening of congestive heart failure in amyloid heart disease treated by calcium channel-blocking agents. American Journal of Cardiology, 1985, 55, 1645.	1.6	136

#	ARTICLE	IF	CITATIONS
469	Primary systemic amyloidosis. Comparison of melphalan/prednisone versus colchicine. American Journal of Medicine, 1985, 79, 708-716.	1.5	159
470	Multiple myeloma: Current therapy and a glimpse of the future. Scandinavian Journal of Haematology, 1985, 35, 38-47.	0.0	15
471	Factor X deficiency in amyloidosis: A critical review. American Journal of Hematology, 1981, 11, 443-450.	4.1	151
472	Immunoperoxidase staining of bone marrow sections. Cancer, 1981, 48, 2438-2446.	4.1	23
473	Amyloidosis:. International Journal of Dermatology, 1981, 20, 75-80.	1.0	10
474	Amyloidosis: Part 1. International Journal of Dermatology, 1980, 19, 537-539.	1.0	11
475	Factor X Deficiency in Primary Amyloidosis. New England Journal of Medicine, 1979, 301, 1050-1051.	27.0	112
476	IgG Subclasses: Relationship to Clinical Aspects of Multiple Myeloma and Frequency Distribution among Components. Scandinavian Journal of Haematology, 1974, 12, 60-68.	0.0	22
477	IgG Cryoglobulinemia Associated With Amyloidosis. Blood, 1973, 41, 569-576.	1.4	3
478	Incidence of Monoclonal Proteins in a Minnesota Community With a Cluster of Multiple Myeloma. Blood, 1972, 40, 719-724.	1.4	179
479	"Intermediate" Cell Types and Mixed Cell Proliferation in Multiple Myeloma: Electron Microscopic Observations. Blood, 1966, 27, 212-226.	1.4	37
480	Orthostatic Hypotension as a Clue to Primary Systemic Amyloidosis. Circulation, 1966, 34, 883-888.	1.6	50
481	Porphyria Cutanea Tarda Associated with Chronic Granulocytic Leukemia Treated with Busulfan (Myleran). Blood, 1964, 23, 776-785.	1.4	32
482	"Primary" Systemic Amyloidosis and Myeloma. Archives of Internal Medicine, 1961, 107, 344.	3.8	109